Innovative drug revenue shows strong growth; biopharmaceutical companies' performance includes a high "new" component

People’s Finance News, March 30 - Benefiting from the improvement in industry prosperity, continuous expansion into overseas markets, and the rollout of favorable pharmaceutical policies, by 2025, A-share biopharmaceutical companies are gradually moving from a long-term “money-burning R&D” phase into a new phase of “profit realization,” continuously achieving innovative results in resilient development. According to Wind data, as of March 29, more than 70 biopharmaceutical companies have released their performance reports for 2025. Among them, 61 companies achieved profitability, accounting for nearly 90%; 29 companies reported positive year-on-year growth in net profit attributable to shareholders (excluding those that turned profitable), with 7 companies achieving a doubling of performance. In addition, companies such as Rongchang Bio, Nuocheng Jianhua, and Digital Human are expected to turn losses into profits, while companies such as Mengke Pharmaceutical, Junshi Biosciences, and Maiwei Bio have reported reductions in losses year-on-year. From the 2025 annual reports that have been released, driven by the introduction of major innovative drug products, many pharmaceutical companies are entering a harvest period, with 35 companies expected to achieve year-on-year growth in net profit or turn losses into profits or reduce losses by 2025. (Shanghai Securities Journal)